Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Malón · SciRah

Researcher profile · Semantic Scholar

D. Malón

Share profile

D. Malón — researcher profile on SciRah

h-index: 9
Works: 33
Citations: 271

Most-cited papers

Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients
B. Losada, J. Guerra, D. Malón, C. Jara +2 more
2018Clinical and Translational Oncology59 citations
Semantic Scholar
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer
M. Quintela-Fandino, S. Morales, A. Cortés-Salgado, L. Manso +12 more
2019Clinical Cancer Research38 citations Open access
Semantic Scholar
Adjuvant chemotherapy for stages II, III and IV of colon cancer
C. Grávalos, I. García-Escobar, P. García-Alfonso, J. Cassinello +2 more
2009Clinical and Translational Oncology37 citations
Semantic Scholar
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
M. Quintela-Fandino, E. Holgado, L. Manso, S. Morales +18 more
2020Breast Cancer Research29 citations Open access
Semantic Scholar
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
M. Quintela-Fandino, J. V. Apala, D. Malón, S. Mourón +4 more
2019Breast Cancer Research16 citations Open access
Semantic Scholar
miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
A. Romero-Lorca, A. Novillo, M. Gaibar, María Fuencisla Gilsanz +6 more
2021Pharmacogenomics and Personalized Medicine13 citations Open access
Semantic Scholar
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
L. Manso, C. Hernando, M. Galán, M. Oliveira +31 more
2020Breast12 citations Open access
Semantic Scholar
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
E. Ciruelos, A. Montaño, C. Rodríguez, E. González-Flores +16 more
2020European Journal of Cancer Care10 citations Open access
Semantic Scholar
Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis
Y. Berner-Wygoda, E. Amir, P. Blumenfeld, Meredith Li +5 more
2025Advances in Radiation Oncology9 citations Open access
Semantic Scholar
Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
A. Novillo, M. Gaibar, A. Romero-Lorca, María Fuencisla Gilsanz +6 more
2020World Journal of Gastroenterology9 citations Open access
Semantic Scholar
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
M. Gaibar, Miguel Galán, A. Romero-Lorca, B. Antón +4 more
2021International Journal of Molecular Sciences7 citations Open access
Semantic Scholar
FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
M. Gaibar, A. Novillo, A. Romero-Lorca, D. Malón +3 more
2022Pharmaceutics6 citations Open access
Semantic Scholar
Biliary cystadenocarcinoma with mesenchymal stroma
C. Gomez-Martin, A. Rodriguez, D. Malón, H. Cortés-Funés
2010Clinical and Translational Oncology6 citations
Semantic Scholar
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor
D. Malón, C. Molto, S. Prasla, Danielle Cuthbert +9 more
2024Breast Cancer Research and Treatment5 citations Open access
Semantic Scholar
HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
A. Novillo, M. Gaibar, A. Romero-Lorca, D. Malón +3 more
2023Cancers5 citations Open access
Semantic Scholar
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
S. Mourón, M. J. Bueno, M. Muñoz, Raúl Torres +10 more
2023JNCI Cancer Spectrum3 citations Open access
Semantic Scholar
Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
Jose María Rodríguez-Piñas, A. Romero-Lorca, M. Gaibar, Apolonia Novillo +15 more
2025Biomedicines2 citations Open access
Semantic Scholar
Abstract P1-02-02: Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): safety and efficacy analysis
Neha Pathak, Sudhir Kumar, Y. Berner-Wygoda, A. Mittal +7 more
2025Clinical Cancer Research2 citations
Semantic Scholar
Abstract OT2-20-01: Rogaratinib, palbociclib and fulvestrant in advanced hormone receptor-positive (HR+), FGFR1/2-positive breast cancer: Phase I trial plus an expansion cohort
S. Pernas, C. Hernando, B. Bermejo, N. Martínez-Jañez +9 more
2022Cancer Research2 citations
Semantic Scholar
Abstract OT2-19-08: Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6
L. Manso, A. Cortés, J. Cejalvo, S. Morales +9 more
2022Cancer Research1 citations
Semantic Scholar
Tumor-derived microRNAs as early predictive biomarkers for toxicity induced by immunotherapy in urothelial cancer
M. Gaibar, A. Romero-Lorca, Jose María Rodríguez-Piñas, Margarita Rubio +12 more
2026Journal of Cancer Research and Clinical Oncology0 citations Open access
Semantic Scholar
Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer.
Y. Berner-Wygoda, Meredith Li, Chloe Perlon, D. Malón +6 more
2025Clinical Breast Cancer0 citations
Semantic Scholar
Abstract P3-07-03: Real-world comparison of safety and effectiveness of dose dense (2-weekly) versus weekly paclitaxel given with trastuzumab as neoadjuvant treatment in HER2-positive early stage breast cancer
Y. Berner-Wygoda, E. Amir, Chloe Perlon, D. Malón +5 more
2025Clinical Cancer Research0 citations
Semantic Scholar
Abstract P4-07-45: Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)
S. A. Novoa, C. Rodríguez, J. Cruz, S. López-Tarruella +20 more
2023Cancer Research0 citations
Semantic Scholar
Abstract P4-07-30: Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
I. Álvarez, A. Guerrero-Zotano, A. Tibau, C. Falo +20 more
2023Cancer Research0 citations
Semantic Scholar
Abstract PS7-35: Geicam/2014-03 (registem): A prospective registry of advanced breast cancer: A subset of triple negative breast cancer patients with her2 low expression
C. Jara, I. Álvarez, C. Rodríguez, P. Martínez +16 more
20210 citations
Semantic Scholar
Abstract PS5-22: Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM)
A. Guerrero-Zotano, C. Jara, S. López-Tarruella, C. Rodríguez +19 more
20210 citations
Semantic Scholar
Metabolic synthetic lethality: a randomized, phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.
M. Quintela-Fandino, S. Morales, A. Cortés, L. Manso +13 more
20190 citations
Semantic Scholar
Abstract OT2-07-02: CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial
A. Cortés, J. V. Apala, D. Malón, J. Guerra +6 more
20180 citations
Semantic Scholar
Abstract P4-21-16: Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)
E. Ciruelos, A. Montaño, C. Rodríguez, E. González-Flores +15 more
20170 citations
Semantic Scholar
Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).
L. Rodríguez, J. Guerra, D. Malón, Rodriguez Laura +2 more
20160 citations
Semantic Scholar
Objective evaluation of physical activity in Spanish breast cancer survivors.
B. Cantos, C. Maximiano, L. Brea, Javier Ramos +12 more
20150 citations
Semantic Scholar
Abstract P3-08-17: Objectively measured physical activity in breast cancer survivors
A. Soria, I. Pagola, M. J. Ortega, L. Brea +8 more
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Guerra×10
Invite
J. Guerra — researcher profile on SciRah
M. Quintela-Fandino×9
Invite
M. Quintela-Fandino — researcher profile on SciRah
S. Mourón×8
Invite
S. Mourón — researcher profile on SciRah
A. Romero-Lorca×7
Invite
A. Romero-Lorca — researcher profile on SciRah

×7

Invite

M. Gaibar — researcher profile on SciRah

A. Fernández-Santander×7

Invite

A. Fernández-Santander — researcher profile on SciRah

C. Rodríguez×7

Invite

C. Rodríguez — researcher profile on SciRah

Invite

S. Morales — researcher profile on SciRah

Invite

L. Manso — researcher profile on SciRah

Invite

J. V. Apala — researcher profile on SciRah

L. González-Cortijo×6

Invite

L. González-Cortijo — researcher profile on SciRah

Invite

A. Novillo — researcher profile on SciRah